 |
Actas Urol Esp (Engl Ed)
- CALDERON CORTEZ JF, Territo A, Fontana M, Gaya JM, et al
Primary urethral carcinoma: Results from a single center experience.
Actas Urol Esp (Engl Ed). 2022;46:70-77.
PubMed
Abstract available
Adv Mater
- CONG Z, Tang S, Xie L, Yang M, et al
Magnetic-Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active
and Targeted Virotherapy of Bladder Cancer.
Adv Mater. 2022 Apr 22:e2201042. doi: 10.1002/adma.202201042.
PubMed
Abstract available
Am J Surg Pathol
- IAKYMENKO OA, Briski LM, Delma KS, Jorda M, et al
Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone
34betaE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From
Prostatic Stromal Invasion.
Am J Surg Pathol. 2022;46:454-463.
PubMed
Abstract available
Anticancer Drugs
- FUKATA S, Mizutani K, Yamamoto S, Kuno T, et al
Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as
predictors of pembrolizumab efficacy in advanced urothelial carcinoma.
Anticancer Drugs. 2022;33:459-466.
PubMed
Abstract available
ANZ J Surg
- BHAMIDIPATY M, Rickard MJFX
An ileal conduit retroperitoneal-pexy: An novel operative technique to treat the
rare colonic internal hernia.
ANZ J Surg. 2022;92:586-587.
PubMed
Arch Esp Urol
- WANG F, Yang J
Correlations between forkhead box D1 expression and clinicopathological
characteristics of patients with bladder cancer and influence on biological
behaviors of bladder cancer cells.
Arch Esp Urol. 2022;75:274-281.
PubMed
Abstract available
- ELIZALDE BENITO FX, Sieso Gracia MR, Dolezal P, Martin Anoro LF, et al
Abdominal mass as the first manifestation of bladder tumor.
Arch Esp Urol. 2022;75:306-307.
PubMed
- RUIBAL GAGO L
[Altered urinary pH as an aetiology of granulomas in urostomised patients.]
Arch Esp Urol. 2022;75:296-299.
PubMed
Abstract available
- SALAS E, Enguita L, Espilez R, Santander C, et al
[Lymphoepithelioma-like bladder tumor. A rare variant.]
Arch Esp Urol. 2022;75:300-305.
PubMed
Abstract available
- LEI Y, Jiao D, Yao Z, Wang L, et al
Prognostic values of preoperative neutrophil-to-lymphocyte ratio,
platelet-to-lymphocyte ratio and lymphocyte- to-monocyte ratio for patients with
muscle- invasive bladder cancer undergoing radical cystectomy.
Arch Esp Urol. 2022;75:287-294.
PubMed
Abstract available
Bioengineered
- XIA Y, Ge M, Xia L, Shan G, et al
CTSV (cathepsin V) promotes bladder cancer progression by increasing NF-kappaB
activity.
Bioengineered. 2022;13:10180-10190.
PubMed
Abstract available
- CHENG J, Yang Q, Han X, Wang H, et al
Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1
upregulation facilitates esophageal carcinoma progression via the
microRNA-5590-3p/programmed cell death-ligand 1 pathway.
Bioengineered. 2022;13:10244-10257.
PubMed
Abstract available
BJU Int
- LEBRET T, Pignot G, Colombel M, Guy L, et al
Artificial intelligence to improve cytology performances in bladder carcinoma
detection: results of the VisioCyt test.
BJU Int. 2022;129:356-363.
PubMed
Abstract available
- LEUNBACH TL, Stilling C, Tabor MB, Bjerggaard Jensen J, et al
Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the
urinary bladder.
BJU Int. 2022;129:457-459.
PubMed
- SUBIELA JD, Rodriguez Faba O, Aumatell J, Calderon J, et al
Contemporary outcomes of bladder carcinoma in situ treated with an adequate
bacille Calmette-Guerin immunotherapy.
BJU Int. 2022;129:542-550.
PubMed
Abstract available
- HASHEM A, Abdellutif MM, Laymon M, Abdullateef M, et al
Clinical efficacy of mebeverine for persistent nocturnal enuresis after
orthotopic W-neobladder.
BJU Int. 2022;129:387-393.
PubMed
Abstract available
BMJ Case Rep
- SINGH YP, Roy D, Jois B, Shetti M, et al
Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin
for papillary carcinoma of bladder.
BMJ Case Rep. 2022;15.
PubMed
Abstract available
BMJ Open
- BIERI U, Scharl M, Sigg S, Szczerba BM, et al
Prospective observational study of the role of the microbiome in BCG
responsiveness prediction (SILENT-EMPIRE): a study protocol.
BMJ Open. 2022;12:e061421.
PubMed
Abstract available
- AL-ZUBAIDI M, Viswambaram P, McCombie S, Liow E, et al
(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer
Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for
urothelial carcinoma.
BMJ Open. 2022;12:e060478.
PubMed
Abstract available
Br J Cancer
- DE JONG JJ, Valderrama BP, Perera J, Juanpere N, et al
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile
associated with unfavorable prognosis.
Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01799.
PubMed
Abstract available
Can J Urol
- TEPLITSKY SL, Hensley PJ, Bettis A, James A, et al
Operative duration and short term morbidity and mortality following radical
cystectomy with urinary diversion.
Can J Urol. 2022;29:11087-11094.
PubMed
Abstract available
Cancer Commun (Lond)
- HUANG M, Dong W, Xie R, Wu J, et al
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer
via a novel PRMT5-WDR5-dependent transcriptional program.
Cancer Commun (Lond). 2022 Apr 18. doi: 10.1002/cac2.12284.
PubMed
Abstract available
Cancer Cytopathol
- NOJIMA S, Terayama K, Shimoura S, Hijiki S, et al
A deep learning system to diagnose the malignant potential of urothelial
carcinoma cells in cytology specimens.
Cancer Cytopathol. 2021;129:984-995.
PubMed
Abstract available
Cancer Gene Ther
- ZHANG Y, Liu Z, Wang X, Jian H, et al
SHMT2 promotes cell viability and inhibits ROS-dependent, mitochondrial-mediated
apoptosis via the intrinsic signaling pathway in bladder cancer cells.
Cancer Gene Ther. 2022 Apr 14. pii: 10.1038/s41417-022-00470.
PubMed
Abstract available
Cancer Med
- LIU T, Li T, Zheng Y, Xu X, et al
Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for
the treatment of bladder cancer.
Cancer Med. 2022 Apr 20. doi: 10.1002/cam4.4745.
PubMed
Abstract available
Cell Death Dis
- HWANG TI, Chen PC, Tsai TF, Lin JF, et al
Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in
chemotherapy and suppresses tumor growth and muscle invasion.
Cell Death Dis. 2022;13:390.
PubMed
Abstract available
CPT Pharmacometrics Syst Pharmacol
- MASTERS JC, Khandelwal A, di Pietro A, Dai H, et al
Model-informed drug development supporting the approval of the avelumab flat-dose
regimen in patients with advanced renal cell carcinoma.
CPT Pharmacometrics Syst Pharmacol. 2022;11:458-468.
PubMed
Abstract available
Curr Cancer Drug Targets
- ZHAO Y, Che J, Tian A, Zhang G, et al
PBX1 Participates in Estrogen-Mediated Bladder Cancer Progression and
Chemo-Resistance Affecting Estrogen Receptors.
Curr Cancer Drug Targets. 2022 Apr 13. pii: CCDT-EPUB-122508.
PubMed
Abstract available
Curr Oncol Rep
- SHVERO A, Hubosky SG
Management of Upper Tract Urothelial Carcinoma.
Curr Oncol Rep. 2022;24:611-619.
PubMed
Abstract available
- KUMAR D, Adeniran AJ
Clinicopathological Review of Micropapillary Urothelial Carcinoma.
Curr Oncol Rep. 2022;24:603-610.
PubMed
Abstract available
Eur J Cancer
- SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
Primary results of STRONG: An open-label, multicenter, phase 3b study of
fixed-dose durvalumab monotherapy in previously treated patients with urinary
tract carcinoma.
Eur J Cancer. 2022;163:55-65.
PubMed
Abstract available
Eur Urol
- HENSLEY PJ, Kamat AM
Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma
Molecular Subtypes.
Eur Urol. 2022;81:316-317.
PubMed
- SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular
Subtypes.
Eur Urol. 2022;81:523-532.
PubMed
Abstract available
- SAAD S, Osman NI, Chapple CR
Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to
the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female
Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
Eur Urol. 2022;81:e16-e17.
PubMed
- CATHOMAS R, Lorch A, Bruins HM, Comperat EM, et al
The 2021 Updated European Association of Urology Guidelines on Metastatic
Urothelial Carcinoma.
Eur Urol. 2022;81:95-103.
PubMed
Abstract available
- CARMEN MIR M, Greenwell T, O'Kelly F, Proietti S, et al
Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele
Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the
Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur
Urol 2021;80
Eur Urol. 2022;81:e26-e27.
PubMed
- DEV S
Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele
Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the
Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur
Urol 2021;80
Eur Urol. 2022;81:e25.
PubMed
- RUTKA JT, Fleshner N, Nathens AB
Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A
Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology
Meetings. Euro Urol 2021;80:442-9.
Eur Urol. 2022;81:e51.
PubMed
- CLEMENTS MB, Atkinson TM, Dalbagni GM, Li Y, et al
Health-related Quality of Life for Patients Undergoing Radical Cystectomy:
Results of a Large Prospective Cohort.
Eur Urol. 2022;81:294-304.
PubMed
Abstract available
- SHIGETA K, Matsumoto K, Oya M
Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the
Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does
Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract
Urothelial
Eur Urol. 2022;81:e20-e21.
PubMed
- MCGREGOR B, O'Donnell PH, Balar A, Petrylak D, et al
Health-related Quality of Life of Patients with Locally Advanced or Metastatic
Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1
Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
Eur Urol. 2022;81:515-522.
PubMed
Abstract available
- GALLIOLI A, Breda A, Palou J
Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in
Upper Tract Urothelial Carcinoma: An International Collaborative Study.
Eur Urol. 2022;81:428-429.
PubMed
- GEAVLETE P, Multescu R, Geavlete B
Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the
Pandemic of COVID-19?
Eur Urol. 2022;81:543.
PubMed
- LIEDBERG F, Abrahamsson J, Bobjer J
Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does
Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract
Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In
press. https://doi.org/
Eur Urol. 2022;81:e18-e19.
PubMed
- NAKAUMA-GONZALEZ JA, Rijnders M, van Riet J, van der Heijden MS, et al
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic
Subtypes of Metastatic Urothelial Carcinoma.
Eur Urol. 2022;81:331-336.
PubMed
Abstract available
Eur Urol Focus
- GRUNEWALD CM, Niegisch G, Albers P
Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer:
IMvigor010 and IMvigor011.
Eur Urol Focus. 2022 Apr 18. pii: S2405-4569(22)00078.
PubMed
Abstract available
Exp Clin Transplant
- KEENAN RA, Haroon U, Ryan P, Harrington B, et al
Management of Urological Malignancy in Heart and Lung Transplant Recipients: An
Irish National Cohort Study.
Exp Clin Transplant. 2021;19:1069-1075.
PubMed
Abstract available
Front Cell Dev Biol
- GU H, Liang C
Construction and Validation of a 15-Top-prognostic-gene-based Signature to
Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for
Bladder Cancer Patients.
Front Cell Dev Biol. 2022;10:725024.
PubMed
Abstract available
Front Genet
- LIU Q, Wang Y, Gao H, Sun F, et al
An Individualized Prognostic Signature for Clinically Predicting the Survival of
Patients With Bladder Cancer.
Front Genet. 2022;13:837301.
PubMed
Abstract available
Hum Vaccin Immunother
- HE L, Wang X, Li C, Wan Y, et al
Bibliometric analysis of the 100 top-cited articles on immunotherapy of
urological cancer.
Hum Vaccin Immunother. 2022;18:2035552.
PubMed
Abstract available
Indian J Pathol Microbiol
- YAMUC E, Barisik NO, Sensu S, Tarhan F, et al
Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and
prognostic factors in superficial urothelial urinary bladder carcinomas.
Indian J Pathol Microbiol. 2022;65:355-361.
PubMed
Abstract available
Investig Clin Urol
- TAE BS, Oh JJ, Jeong BC, Ku JH, et al
Catheter-associated urinary tract infections in patients who have undergone
radical cystectomy for bladder cancer: A prospective randomized clinical study of
two silicone catheters (clinical benefit of antibiotic silicone material).
Investig Clin Urol. 2022 Mar 28. pii: 63.e32. doi: 10.4111/icu.20210436.
PubMed
Abstract available
Iran J Basic Med Sci
- RAZZAGHDOUST A, Muhammadnejad S, Parvin M, Mofid B, et al
Development and immunohistochemical characterization of patient-derived xenograft
models for muscle invasive bladder cancer.
Iran J Basic Med Sci. 2021;24:1650-1655.
PubMed
Abstract available
J Cancer Res Clin Oncol
- CARRIL-AJURIA L, Martin-Soberon MC, de Velasco G, Agarwal N, et al
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a
comprehensive review.
J Cancer Res Clin Oncol. 2022;148:1097-1105.
PubMed
Abstract available
J Clin Oncol
- SONPAVDE GP, Mouw KW, Mossanen M
Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
J Clin Oncol. 2022;40:1275-1280.
PubMed
Abstract available
J Clin Pathol
- COLLA RUVOLO C, Wurnschimmel C, Wenzel M, Nocera L, et al
Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta
urothelial carcinoma of urinary bladder.
J Clin Pathol. 2022;75:333-337.
PubMed
Abstract available
J Endourol
- BUBE SH, Kingo PS, Madsen MG, Vasquez JL, et al
Validation of a Novel Assessment Tool Identifying Proficiency in Transurethral
Bladder Tumor Resection: The OSATURBS Assessment Tool.
J Endourol. 2022;36:572-579.
PubMed
Abstract available
- SARI MOTLAGH R, Rajwa P, Mori K, Laukhtina E, et al
Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En
Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A
Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on
Different Energy So
J Endourol. 2022;36:535-547.
PubMed
Abstract available
J Histochem Cytochem
- HARDY CSC, Ghaedi H, Slotman A, Sjodahl G, et al
Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing
Parsimony and Performance of Lund Taxonomy Classifiers.
J Histochem Cytochem. 2022 Apr 19:221554221095530.
PubMed
Abstract available
J Immunol Res
- ZHAO H, Chen Z, Fang Y, Su M, et al
Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
J Immunol Res. 2022;2022:1793005.
PubMed
Abstract available
JAMA Netw Open
- LEWICKI P, Basourakos SP, Arenas-Gallo C, Qiu Y, et al
Use of Intravesical Chemotherapy in the US Following Publication of a Randomized
Clinical Trial.
JAMA Netw Open. 2022;5:e220602.
PubMed
Mol Carcinog
- CHEN X, Ou Z, Wang L, Zhang Z, et al
Association of tumor mutational burden with genomic alterations in Chinese
urothelial carcinoma.
Mol Carcinog. 2022;61:311-321.
PubMed
Abstract available
Mol Cell Biochem
- DIETRICH F, Cappellari AR, Filippi-Chiela EC, de Paula PB, et al
High P2X6 receptor expression in human bladder cancer predicts good survival
prognosis.
Mol Cell Biochem. 2022 Apr 16. pii: 10.1007/s11010-022-04425.
PubMed
Abstract available
Nat Commun
- SU Z, Monshaugen I, Wilson B, Wang F, et al
TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates
gene-silencing activity and the unfolded protein response in bladder cancer.
Nat Commun. 2022;13:2165.
PubMed
Abstract available
Nihon Hinyokika Gakkai Zasshi
- MATSUMURA S, Yoshida T, Imanaka T, Yamanaka K, et al
[OUTCOMES OF BLADDER CANCER IN NONAGENARIANS].
Nihon Hinyokika Gakkai Zasshi. 2021;112:58-64.
PubMed
Abstract available
- MAEDA K, Mori Y, Nakamura M, Harada Y, et al
[SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION AS A SIDE EFFECT OF
CHEMOTHERAPY FOR URACHAL CARCINOMA: A CASE REPORT].
Nihon Hinyokika Gakkai Zasshi. 2021;112:100-104.
PubMed
Abstract available
- UEMURA T, Ishibashi T, Pae S, Shirakawa N, et al
[CLINICAL STUDY OF OPEN RADICAL CYSTECTOMY AND ILEAL CONDUIT CONSTRUCTION FOR
BLADDER CANCER: RESULTS OF 15-YEAR SINGLE CENTER EXPERIENCE].
Nihon Hinyokika Gakkai Zasshi. 2021;112:89-95.
PubMed
Abstract available
Open Vet J
- NISHIMORI T, Hanazono K, Matsuda K, Kawamura Y, et al
Prognostic role of DeltaNp63 expression in canine transitional cell carcinoma of
the urinary bladder.
Open Vet J. 2021;11:700-706.
PubMed
Abstract available
- GOVONI VM, Pigoli C, Sueiro FAR, Zuliani F, et al
Lymphatic invasion is a significant indicator of poor patient outcome in canine
bladder urothelial carcinoma.
Open Vet J. 2021;11:535-543.
PubMed
Abstract available
Optom Vis Sci
- CLAIBORNE RT, Tsan GL
Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
Optom Vis Sci. 2022;99:88-92.
PubMed
Abstract available
Pathol Res Pract
- WANG SS, Zhai GQ, Chen G, Huang ZG, et al
Decreased expression of transcription factor Homeobox A11 and its potential
target genes in bladder cancer.
Pathol Res Pract. 2022;233:153847.
PubMed
Abstract available
PeerJ
- HUANG Z, Gao H, Qing L, Wang B, et al
A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer
by inhibiting the Wnt/betacatenin signaling pathway.
PeerJ. 2022;10:e13220.
PubMed
Abstract available
PLoS One
- KANG DH, Cho KS, Moon YJ, Chung DY, et al
Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0
bladder cancer: A systematic review and meta-analysis according to EAU COVID-19
recommendation.
PLoS One. 2022;17:e0267410.
PubMed
Abstract available
Prog Urol
- ROLLIN P, Xylinas E, Lanz C, Audenet F, et al
[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC:
Feasability study from CC-AFU vessie].
Prog Urol. 2022;32:326-331.
PubMed
Abstract available
RSC Adv
- FISHER L
Retraction: Exosome-derived PTENP1 suppresses cisplatin resistance of bladder
cancer (BC) by suppressing cell proliferation, migration and inducing apoptosis
via the miR-103a/PDCD4 axis.
RSC Adv. 2021;11:6254.
PubMed
Abstract available
Semin Ophthalmol
- ALKAN S, Evlice O, Agin A
The Evaluation of Cases with Ocular Complications due to Bacillus Calmette-Guerin
(BCG) Treatment using the Pool Analysis Method.
Semin Ophthalmol. 2022;37:373-378.
PubMed
Abstract available
Support Care Cancer
- MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus
Calmette-Guerin treatment-induced sleep quality deterioration in patients with
non-muscle invasive bladder cancer.
Support Care Cancer. 2022 Apr 14. pii: 10.1007/s00520-022-07043.
PubMed
Abstract available
- JUNG A, Crandell JL, Nielsen ME, Smith SK, et al
Relationships among uncertainty, post-traumatic stress disorder symptoms, and
quality of life in non-muscle-invasive bladder cancer survivors.
Support Care Cancer. 2022 Apr 18. pii: 10.1007/s00520-022-07034.
PubMed
Abstract available
Ther Adv Urol
- D'ELIA C, Trenti E, Krause P, Pycha A, et al
Xpert(R) bladder cancer detection as a diagnostic tool in upper urinary tract
urothelial carcinoma: preliminary results.
Ther Adv Urol. 2022;14:17562872221090320.
PubMed
Abstract available
Urol Oncol
- DANESHMAND S, Brummelhuis ISG, Pohar KS, Steinberg GD, et al
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical
drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a
phase I trial.
Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00059.
PubMed
Abstract available
- SORCE G, Chierigo F, Flammia RS, Hoeh B, et al
Survival trends in chemotherapy exposed metastatic bladder cancer patients and
chemotherapy effect across different age, sex, and race/ethnicity.
Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00105.
PubMed
Abstract available
- LI Z, Zhang Z, Ma H, Yao K, et al
Extraperitonealization of ileal conduit reduces parastomal hernia after
cystectomy and ileal conduit diversion.
Urol Oncol. 2022;40:162.
PubMed
Abstract available
- MUZAAIL HH, El-Assmy A, Harraz AM, Awadalla A, et al
Prediction of recurrence of non-muscle invasive bladder cancer: The role of
androgen receptor and miRNA-2909.
Urol Oncol. 2022 Apr 13. pii: S1078-1439(22)00078.
PubMed
Abstract available
- GONZALEZ-PADILLA DA, Subiela JD, Gonzalez-Diaz A, Hernandez-Arroyo M, et al
Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle
invasive bladder cancer treatment: A retrospective cohort from a high-volume
center.
Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00067.
PubMed
Abstract available
- PIERCONTI F, Martini M, Cenci T, Fiorentino V, et al
The bladder epicheck test and cytology in the follow-up of patients with
non-muscle-invasive high grade bladder carcinoma.
Urol Oncol. 2022;40:108.
PubMed
Abstract available
- WOO S, Ghafoor S, Das JP, Gangai N, et al
Plasmacytoid urothelial carcinoma of the bladder: MRI features and their
association with survival.
Urol Oncol. 2022;40:108.
PubMed
Abstract available
- YANG CH, Weng WC, Ou YC, Lin YS, et al
Diffusive Ki67 and vimentin are associated with worse recurrence-free survival of
upper tract urothelial carcinoma: A retrospective cohort study from bench to
bedside.
Urol Oncol. 2022;40:109.
PubMed
Abstract available
- LYON TD, Faraj KS, Brennan E, Tyson MD 2nd, et al
Defining radical cystectomy using the ICD-10 procedure coding system.
Urol Oncol. 2022;40:165.
PubMed
Abstract available
- FLAMMIA RS, Chierigo F, Wurnschimmel C, Horlemann B, et al
Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal
carcinoma.
Urol Oncol. 2022;40:165.
PubMed
Abstract available
- PARK CK, Cho NH
Differences in genomic profile of high-grade urothelial carcinoma according to
tumor location.
Urol Oncol. 2022;40:109.
PubMed
Abstract available
- VENKAT S, Khan AI, Lewicki PJ, Borregales L, et al
Novel nomograms to predict muscle invasion and lymph node metastasis in upper
tract urothelial carcinoma.
Urol Oncol. 2022;40:108.
PubMed
Abstract available
- AYDIN AM, Reich RR, Cao B, Cheriyan SK, et al
Clinical indications for necessary and discretionary hospital readmissions after
radical cystectomy.
Urol Oncol. 2022;40:164.
PubMed
Abstract available
- YU A, Wang Y, Mossanen M, Preston M, et al
Robotic-assisted radical cystectomy is associated with lower perioperative
mortality in octogenarians.
Urol Oncol. 2022;40:163.
PubMed
Abstract available
- ALBISINNI S, Diamand R, Mjaess G, Assenmacher G, et al
Continuing acetylsalicylic acid during Robotic-Assisted Radical Cystectomy with
intracorporeal urinary diversion does not increase hemorrhagic complications:
results from a large multicentric cohort.
Urol Oncol. 2022;40:163.
PubMed
Abstract available
- RANTI D, Pfail J, Garcia M, Razdan S, et al
Neobladder creation in patients with chronic kidney disease: A viable diversion
strategy.
Urol Oncol. 2022;40:168.
PubMed
Abstract available
- TAOKA R, Kobayashi T, Hidaka Y, Abe H, et al
Impact of prior intravesical bacillus Calmette-Guerin therapy on the
effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Urol Oncol. 2022;40:107.
PubMed
Abstract available
- SHIGETA K, Matsumoto K, Ogihara K, Murakami T, et al
Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper
tract urothelial carcinoma? Results of a multi-center cohort study.
Urol Oncol. 2022;40:105.
PubMed
Abstract available
- CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
Comparative effectiveness analysis of first-line immunotherapy versus
chemotherapy in metastatic urothelial carcinoma of the bladder.
Urol Oncol. 2022;40:107.
PubMed
Abstract available
- MITCHELL KA, Williams H
Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer
health disparities outcomes.
Urol Oncol. 2022;40:126-132.
PubMed
Abstract available
World J Urol
- GUO B, Liu M
The role of chemotherapy in patients with pure squamous cell bladder carcinoma.
World J Urol. 2022;40:865-866.
PubMed
Zhonghua Zhong Liu Za Zhi
- XU H, Shi HL, Hao JW, Shu KP, et al
[Casticin inhibits the proliferation, migration and invasion of bladder cancer
cells by inhibition of TM7SF4 expression].
Zhonghua Zhong Liu Za Zhi. 2022;44:334-340.
PubMed
Abstract available
|
AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to
a media sponsorship by
Boehringer Ingelheim.
Design:
|